Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Given a $3.00 Price Target by Maxim Group Analysts

Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report sent to investors on Tuesday, June 4th, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Actinium Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, June 4th. Oppenheimer set a $5.00 price target on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, February 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $3.45.

ATNM stock remained flat at $$0.25 during mid-day trading on Tuesday. The company’s stock had a trading volume of 826,574 shares, compared to its average volume of 1,200,308. Actinium Pharmaceuticals has a 1-year low of $0.23 and a 1-year high of $0.87.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01.

Institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Actinium Pharmaceuticals by 23.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 198,480 shares during the period. Vanguard Group Inc raised its position in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the last quarter. Vanguard Group Inc. raised its position in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in Actinium Pharmaceuticals by 69.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 175,512 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 71,840 shares during the last quarter.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

See Also: Why are trading ranges significant?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.